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ABSTRACT
Objective: To report on a new surgical technique to treat obesity -
Digestive Adaptation - and to present its preliminary results.
Method: The technique includes a vertical (sleeve) gastrectomy,
omentectomy and enterectomy maintaining the initial 150-cm-
portion of the jejunum and the final 150-cm-portion of the ileum.
The three first obese patients operated on are described. Results:
With a minimum follow-up of 6 months, all patients refer early
satiety, are free of symptoms and have a BMI <31 Kg/m2.
Conclusions: This procedure does not use prostheses and does
not cause exclusion of gastrointestinal segments. It does not
create subocclusions neither malabsorption nor blind endoscopic
areas and above all, it causes no harm to important digestive
functions. Conversely, it aims at moderate restriction with early
satiety by distension, and at interfering in the neuroendocrine
profile, resulting in slow gastric emptying, early and prolonged
satiety, as well as positive changes in the metabolic profile. Based
on recent physiological data, the procedure aims at decreasing
the production of ghrelin, plasminogen activator inhibitor-1 (PAI-1)
and resistin, and at raising the levels of glucagon-like peptide-1
(GLP-1). The patients operated on do not need nutritional support
or to take drugs because of the procedure, which is easy and safe
to perform.
Keywords: Obesity, morbid/surgery; Plasminogen activator
inhibitor 1; Omentum/physiology; Adipose tissue/physiopathology;
Gastrectomy/methods, Peptide hormones; Citokines/physiology
RESUMO
Objetivo: Esta é a comunicação preliminar, com resultados iniciais,
de uma nova técnica cirúrgica para tratar a obesidade: Adaptação
Digestiva. Método: A técnica inclui uma gastrectomia vertical, a
omentectomia e enterectomia que mantém os primeiros 150 cm
de jejuno e os últimos 150 cm de íleo. Os três primeiros pacientes
obesos tratados por esta técnica são apresentados. Resultados:
Com seguimento mínimo de seis meses, todos os pacientes estão
livres de sintomas, referem saciedade mais precocemente e já
estão com IMC menor que 31 Kg/m2. Conclusões: Este procedi-
mento evita criar subestenoses, colocar próteses, excluir
segmentos digestivos do trânsito de nutrientes, gerar malabsorção
e fundamentalmente, evita prejudicar funções digestivas. O
procedimento visa gerar uma restrição moderada, o que colabora
para a saciedade precoce por distensão gástrica com menores
volumes e visa também modificar as circunstâncias neuroendó-
crinas, retardando o esvaziamento gástrico, e gerando saciedade
precoce e prolongada, paralelamente a mudanças positivas no
perfil metabólico. Baseado em dados fisiológicos recentemente
descobertos, o procedimento pretende diminuir a produção de
grelina, do inibidor da ativação do plasminogênio 1 (PAI-1), da
resistina e finalmente promover a secreção mais efetiva do
glucagon-like peptide 1 (GLP-1). O paciente operado não necessita
de suporte nutricional nem de uso crônico de medicações por
causa do procedimento, que é simples e fácil de ser realizado.
DESCRITORES: Obesidade mórbida/cirurgia; Inibidor 1 de ativador
de plasminogênio; Omento/fisiologia; Tecido adiposo/fisiopatologia;
Gastrectomia/métodos; Hormônios peptídicos; Citocinas/fisiologia
INTRODUCTION
In the 20th century, we observed a great increase in the
incidence of obesity, hypertension, diabetes, hypertrigly-
ceridemia, hypercholesterolemia, and other conditions
associated with changes in human diet. Nutritional
education and medical treatment have failed to avoideinstein 2003; 1:99-104
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obesity, and many surgical techniques to treat extreme
obesity have been presented although none has been
satisfactory. Current surgical treatment causes “another
disease” to counterbalance obesity. Some techniques
result in malabsorption, yet unspecific, leading to loss
of non-caloric nutrients, such as calcium, iron, folic
acid, etc., and to diarrhea(1). Some procedures pose
obstacles to ingestion of food, and others use prosthesis
that may cause subocclusions(2), and consequently,
dysphagia, vomiting, stasis esophagitis, etc. Many current
procedures involve exclusion of digestive system
segments, which causes atrophy of mucosa with bacterial
proliferation; this, in turn, leads to intense flatulence
and bacterial translocation to the portal system, which
may be related to hepatic fibrosis(3). Additionally,
exclusion of segments hinders endoscopy.
We searched new surgical alternatives, which could be
easy to perform, require no exclusion of any segment,
prevent endoscopic blind areas, avoid strangling prosthesis
and cause no subocclusions. Moreover, the technique
should avoid malabsorption and above all, not harm
important digestive functions. We rather searched
procedures that could positively interfere with the
neuroendocrine control of hunger and satiety.
Physiological Background
GLP-1: Glucagon-like peptide 1 (GLP-1) is a
hormone released by the enteroendocrine L-cells of
the gut in response to food ingestion. GLP-1 increases
both insulin secretion and insulin gene expression and
growth of pancreatic beta-cells(4-6). GLP-1 is secreted
mainly by the distal intestine and the nutrients that
reach this point  are a major stimulus to release this
hormone(7).
GLP-1 is a potent agent that could improve or even
cure type II diabetes(4,8). When obese diabetic patients
are submitted to biliopancreatic diversion (Scopinaro
Technique)(9), the ileogastric anastomosis provides
nutrients straight into the ileum and just after the
operation, and diabetes is markedly improved or cured
before patients lose any significant weight. Efficient
production of GLP-1 is thought to cause this major
benefit.
GLP-1 also has other important actions. It inhibits
gastric emptying(7) and crosses the blood-brain barrier
causing satiety(4,10). In sum, after a big meal, when
nutrients reach the distal intestine, GLP-1 is produced,
increasing the release of insulin and delaying gastric
emptying and causing central satiety.
Ghrelin: It is a 28-amino peptide, predominantly
produced by the stomach and it has intense growth
hormone (GH) releasing activity. Moreover, it
stimulates gastric acid secretion, and can induce excess
adipose tissue by activating a central mechanism to
increase food intake and decrease use of fat(11-13).
Ghrelin production drops after a meal and later on, it
increases - this has been demonstrated as taking part
in the mechanism of hunger(14). High ghrelin levels are
not a common cause of obesity since it was demonstrated
that obese individuals present low levels of this
hormone. However in case of significant weight loss,
the levels of ghrelin raise, resulting in hunger and,
probably, contributing in gaining weight again(15).
PAI-1: Plasminogen activator inhibitor 1 (PAI-1) is
the primary physiological inhibitor of plasminogen
activation and has procoagulation activity. Circulating
PAI-1 levels are elevated in patients with coronary heart
disease and play an important role in the development
of arterial thrombosis by decreasing fibrin degradation(16) .
PAI-1 is produced by visceral fat tissue, mainly the
omentum and mesenteric fat(16-18). Procedures causing
decrease in PAI-1 levels have already been demonstrated
as improving metabolic profile and reducing cardiovascular
risk(19-20).
Resistin: It is clear today that adipose tissue is an
endocrine gland and it produces many substances that
could act like hormones, such as leptin, interleukin-6,
adiponectin (also called ACRP30 and adipoQ),
angiotensin II and resistin. Resistin acts on skeletal
muscle myocytes, hepatocytes, and adipocytes, reducing
their sensitivity to insulin; thus, it is related to
diabetes(21-22). Abdominal fat is the main source of
resistin(22-23).
Visceral obesity: Abdominal fat tissue was clearly
related to the so-called plurimetabolic syndrome. The
waist/hip ratio has been used to quantify cardiovascular
risk and many epidemiological studies have indicated
its relation with high blood pressure, hypertriglyceridemia,
insulin resistance and arterial thrombosis. Visceral fat
is insulin-resistant and therefore releases free fatty acids
(FFA) to the portal system. It is believed that insulin
resistance of the liver derives from a relative increase
in delivery of FFA from the omental fat depot to the
liver (via portal vein)(24). Many extreme obese patients
have quite good metabolic profile because they have
mostly subcutaneous fat. Except for orthopedic and
respiratory complications, as well as reflux, most metabolic
complications of obesity are related to visceral fat.
Evolutionary Background
Primitive diet was raw, full of poorly digestible fiber
and very hypocaloric. The stomachs had to be big
enough to keep an amount of food and handle long
fasting periods. Hence, the volume of food ingested
had to be expressive. The intestines had to be very long
in order to take and process more food and to be
efficient and not loose nutrients. However, the human
diet has deeply changed in few centuries. Fire controleinstein 2003; 1:99-104
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made food more digestible. Agriculture gave us some
abundance and increased the amount of carbohydrates.
Refined sugar may be given to us in considerable
amounts, whereas nature could give us just minimal
portions. Saturated fat and industrialized food made
the picture even worse. The development of electricity
has allowed us to eat also at night. Marketing,
restaurants, cookies, and the other goodies of
civilization have represented a very quick change that
our digestive system and our eating instincts could not
follow yet.
Modern diet is hypercaloric, poor in fiber and easy
to absorb. After a meal with these characteristics,
absorption occurs in the proximal portions of the bowel,
resulting in a peak of nutrient absorption. Distal bowel
tends to absorb less nutrients, and this reduces
production of GLP-1. Indeed, it was noticed that
diabetic(25) and obese people(26) have reduced postprandial
production of GLP-1.
It has also been shown that obese individuals tend
to have longer small bowel than slim patients, and this
is not related to height but to weight(27). This fact
probably contributes to smaller amounts of nutrients
reaching the distal bowel, implying in less signaling of
being fed due to less GLP-1.
Nature now performs what it does best - selection.
Individuals with strong eating instincts are being killed
by lack of adaptation of their digestive system and its
neuroendocrine control.
A new surgical proposal to treat obesity
We have been searching a manner to adapt the
digestive system and eating instincts to abundance,
without causing damage to important digestive
functions, like those performed by the stomach, pylorus,
duodenum, ileum and colon. The duodenum and the
proximal intestine have functions different from the
distal gut. Some current techniques to treat obesity
resect or exclude the pylorus (Scopinaro´s biliopancreatic
bypass(9), Fobi(28) or Capella(29) Roux-en-Y gastric bypass).
In biliopancreatic bypass, using Scopinaro´s technique
or the Duodenal Switch technique(30), the entire proximal
intestine is excluded and the procedure may cause
unspecific malabsorption that leads to nutritional
deficiencies(1). In gastric bypass, most of the stomach is
excluded. Other techniques involve no exclusion but may
cause subocclusion, such as gastric banding(2).
In our point of view, the several digestive functions
are essential, even to obese patients. However, we know
that the gastric capacity is bigger than what modern
diet requires(31). Even the intestines are too long to
modern diet(32). Therefore, we propose a vertical gastric
resection (similar to the extensively used “Duodenal
Switch” technique)(30,33) associated to omentectomy and
a midgut enterectomy that leaves 150 cm of proximal
small bowel and 150 cm of distal small bowel, totaling
3 meters of small bowel, which is still considered a
normal length.
The Research Ethics Committee of Hospital da
Polícia Militar do Estado de São Paulo approved the
protocol. A detailed informed consent was signed by
patients, and it stated weight loss could not be predicted
due to lack of experience.
METHOD
Technique: the procedure may be performed either
through a supraumbilical midline incision or laparoscopy.
The open technique is described here. The first step is
to release the great omentum from the colon. The
gastric fundus is released by cutting the short gastric
vessels with a harmonic scalpel. Later, the gastroepiploic
arcade is interrupted at 6 cm proximal to the pylorus.
Gastroepiploic vessels will remain intact in the antrum.
A 12-mm Fouchet tube is passed through the esophagus
until the duodenum by the lesser curvature. A linear
cutting stapler is used in order to resect the gastric
fundus and most of the gastric body, leaving a gastric
tube of 3 to 4 cm of diameter in the lesser curvature
(figure 1). Gastric specimen and the great omentum
are removed as shown in figure 2.
A protective continuous seromuscular polypropylene
suture is performed over the gastric stapling line. The
procedure is completed with an enterectomy that
removes the midgut, at 150 cm away from Treitz angle
Figure 1. Diagram of partial gastric resectioneinstein 2003; 1:99-104
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and at 150 cm proximal to the ileocecal valve, with its
mesentery (figure 3). And end-to-end (entero-enteral)
anastomosis is the last step.
First patients and results: We report the first three
patients submitted to surgery and their follow-up of at
least 6 months.
Patient 1: MZF, female, 39 years old, weight=104 kg
(229,27 pounds), height =169 cm (5ft7), BMI: 36.4 kg/m2,
total cholesterol=210 mg/dl, triglycerides=200 mg/dl.
She had been under clinical treatment for ten years.
When surgery was indicated she was taking Orlistat,
and had used sibutramine and others drugs before. She
could not loose any weight and complained of pain
related to disk herniation. The patient was operated
in October 2002. In August 2003, her weight was 69 kg
(152 pounds), BMI=24.1 kg/m2; cholesterol=174 mg/dl,
triglycerides=161 mg/dl. She used no medicine and back
pain disappeared.
Figure 3. Specimen of enterectomy. Small bowel of 150 cm in length (patient MZF)
Figure 2. Specimen of gastroepiploic resection
 Patient 2: RJSB, male, 40 years old, weight=143 kg
(315 pounds), height=182 cm (6ft), BMI=43.1 kg/m2,
total cholesterol=247 mg/dl, triglycerides=295 mg/dl.
The patient had been on clinical treatment for ten years,
and was taking Fenproporex. He complained of pain in
the knees and low back pain, and was submitted to surgery
in January 2003. In August 2003, he weighed 100 kg
(220 pounds), BMI=30.1 kg/m2, cholesterol=197 mg/dl;
triglycerides=102 mg/dl. The patient was still loosing
when this article was submitted to publication.
Patient 3: WVBG, male, 44 years old, weight=123 kg
(271 pounds), height=178 cm (5ft10), BMI=38.6 kg/m2,
total cholesterol=247 mg/dl, triglycerides= 295 mg/dl.
The patient had been on clinical treatment for ten
years, and had recently been in use of Orlistat,
Fenproporex and amphetamine. He complained of pain
in the knees and low back pain. The patient was
operated in February 2003. On the 23rd postoperative
day, he returned to hospital due to an abscess that was
drained. In August 2003, he weighed 99 kg (218.2
pounds), BMI=31.2 kg/m2, cholesterol=142 mg/dl;
triglycerides= 67 mg/dl.
All patients received cefazolin for 24 hours as
prophylaxis and were discharged on the third
postoperative day.  They were oriented to take only
liquids, a maximum volume of 150 ml each time, during
one week; later they were allowed to eat solid food.
They were recommended to start meals with a portion
of salad; fruits, vegetables and fish and chicken were
also prescribed. No patient had diarrhea, and two of
them had mild obstipation for eating less. All patients
referred early satiety, had no symptoms and were very
satisfied.
Discussion
The procedure has many advantages and we believe it
could adapt the digestive system to modern diet. Since
current foods are much more caloric than primitive
diet, the gastric capacity is reduced by 1 to 1.8 liters.
However, there is no subocclusion, no stenosis and no
use of prosthesis. The stomach is proportionally
reduced, but keeping its general structure (cardia, body,
antrum and pylorus) and innervation by the lesser
curvature is intact. Early satiety by gastric distension
tends to occur. When significant weight loss occurs,
no raise in ghrelin production is expected since its major
source is removed(14-15).
The enterectomy presented does not aim at causing
malabsorption. There is no report of enteric insufficiency
with 300 cm of a proportional bowel (with duodenum,
jejunum, ileum, ileocecal valve and colon). In fact, some
normal people have just three meters of small boweleinstein 2003; 1:99-104
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(in humans, the small bowel length ranges from 3 to 8
meters)(34).
The intention of this procedure is to create a
proportionally smaller intestine that is still normal and
takes less contents; moreover, it takes nutrients to the
ileum, resulting in a more effective secretion of GLP-
1, which, in turn, reduces gastric emptying speed,
improves insulin secretion and promotes central satiety.
Triglycerides and cholesterol levels are usually reduced
by bowel resections(35).
When enterectomy is performed, the mesentery is
excised and visceral fat is removed.  Omentectomy
promotes additional resection of visceral fat(17) and
reduction of a source of PAI-1(22), reducing the risk of
arterial thrombosis. It provides a reduction in the source
of resistin and free fat acids to the portal vein. Both
events are thought to reduce hyperinsulinism and
insulin resistance (21,24). As the specimens removed are
bulky and  the intraabdominal pressure (IAP) is
reduced. High IAP is related to respiratory and
hemodynamic problems and reflux.
These preliminary results are very encouraging since
patients achieved weight loss as expected and presented
neither subocclusions nor malabsorption. We should
evaluate the drop in ghrelin, resistin, PAI-1 levels and
early raise in GLP-1 levels. Besides the benefits of
weight loss, we observed the expected fall in cholesterol
and triglycerides levels. However, improvement of
metabolic profile must be assessed in a larger sample
and in the long run.
Furthermore, very obese patients may not loose the
amount of weight required with this technique for it is
not aggressive to digestive functions. However, most
techniques previously mentioned may still be used after
the procedure described.
The current surgical procedures for obesity are so
aggressive that may not be recommended to patients
who are not extremely obese. Hence, when these
procedures are performed the patients already present
damaged arteries and joints, and suffer from the
consequences of diabetes, hypertension, dyslipidemia,
gastroesophageal reflux and other conditions associated
with obesity, apart from psychosocial problems. The
surgical risk is higher.
Since the procedure proposed is simple and safe,
preserves the general structure of the organs and
important digestive functions and requires no
nutritional support, it could be recommended to
patients who are not extremely obese, reducing surgical
risk. The procedure itself does not pose much risk.
Extreme obesity is a severe condition, with some
irreversible physical and psychological damage
developed over years. Current treatments comprise
surgeries that are physiologically aggressive. The
technique reported may be a physiologically acceptable
procedure to treat extreme obesity. It could also be
used to prevent extreme obesity in cases it is eminent
and patients already have associated diseases.
This is the first surgical procedure that does not
aim at curing an affected or deficient organ, but it
intends to adapt a system to modern circumstances in
cases  nutritional and medical treatment failed. In fact,
this is an evolutionary and adaptative surgery that
would not be necessary if we had not changed our
primitive diet. It might become a very important
procedure since it can early prevent the development
of obesity, hypertriglyceridemia, hypercholesterolemia,
type II diabetes, hypertension, arterial thrombosis and
other typical conditions of modern life.
CONCLUSION
The procedure presented is the association of three
well-known techniques: vertical gastrectomy, omentectomy
and enterectomy. All are very simple and safe. Together,
they produce a proportionally reduced digestive
system, however not changing its general structure as
observed in other obesity surgery techniques. No
stenosis, subocclusions, excluded segments, malabsorption,
blind endoscopic areas  were created, and no prosthesis
was used. Above all, no harm was caused to important
digestive functions. The patient submitted to surgery
need no nutritional support or chronic use of drugs
due to the procedure. The preliminary results are very
encouraging.
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